Notice2022-06023
Announcement of the Re-Approval of the American Association for Laboratory Accreditation (A2LA) as an Accreditation Organization Under the Clinical Laboratory Improvement Amendments of 1988
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 22, 2022
Effective
March 23, 2022
Issuing agencies
Health and Human Services DepartmentCenters for Medicare & Medicaid Services
Abstract
This notice announces the application of the American Association for Laboratory Accreditation (A2LA) for approval as an accreditation organization for clinical laboratories under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) program. We have determined that the A2LA meets or exceeds the applicable CLIA requirements. In this notice, we announce the approval and grant the A2LA deeming authority for a period of 6 years.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 55 (Tuesday, March 22, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 55 (Tuesday, March 22, 2022)]
[Notices]
[Pages 16190-16192]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-06023]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-3422-N]
Announcement of the Re-Approval of the American Association for
Laboratory Accreditation (A2LA) as an Accreditation Organization Under
the Clinical Laboratory Improvement Amendments of 1988
AGENCY: Centers for Medicare & Medicaid Services (CMS), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces the application of the American
Association for Laboratory Accreditation (A2LA) for approval as an
accreditation organization for clinical laboratories under the Clinical
Laboratory Improvement Amendments of 1988 (CLIA) program. We have
determined that the A2LA meets or exceeds the applicable CLIA
requirements. In this notice, we announce the approval and grant the
A2LA deeming authority for a period of 6 years.
DATES: The approval announced in this notice is effective from March
23, 2022, until March 22, 2028.
FOR FURTHER INFORMATION CONTACT: Cindy Flacks, 410-786-6520.
SUPPLEMENTARY INFORMATION:
I. Background and Legislative Authority
On October 31, 1988, the Congress enacted the Clinical Laboratory
Improvement Amendments of 1988 (CLIA) (Pub. L. 100-578). CLIA amended
section 353 of the Public Health Service Act. We issued a final rule
implementing the accreditation provisions of CLIA on July 31, 1992 (57
FR 33992). Under those provisions, we may grant deeming authority to an
accreditation organization if its requirements for laboratories
accredited under its program are equal to or more stringent than the
applicable CLIA program requirements in 42 CFR part 493 (Laboratory
Requirements). Subpart E of part 493 (Accreditation by a Private,
Nonprofit Accreditation Organization or Exemption Under an Approved
State Laboratory Program) specifies the requirements an accreditation
organization must meet to be approved by CMS as an accreditation
organization under CLIA.
II. Notice of Approval of A2LA as an Accreditation Organization
In this notice, we approve the American Association for Laboratory
Accreditation (A2LA) as an organization that may accredit laboratories
for purposes of establishing their compliance with CLIA requirements in
all specialties and subspecialties. We have examined the initial A2LA
application and all subsequent submissions to determine its
accreditation program's equivalency with the requirements for approval
of an accreditation organization under subpart E of part 493. We have
determined that the A2LA meets or exceeds the applicable CLIA
requirements. We have also determined that the A2LA will ensure that
its accredited laboratories will meet or exceed the applicable
requirements in subparts H, I, J, K, M, Q, and the applicable sections
of subpart R of part 493. Therefore, we grant the A2LA approval as an
accreditation organization under subpart E of part 493, for the period
stated in the DATES section of this notice for all specialties and
subspecialties under CLIA. As a result of this determination, any
laboratory that is accredited by the A2LA during the time period stated
in the DATES section of this notice will be deemed to meet the CLIA
requirements for the listed specialties and subspecialties, and
therefore, will generally not be subject to routine inspections by a
State survey agency to determine its compliance with CLIA requirements.
The accredited laboratory,
[[Page 16191]]
however, is subject to validation and complaint investigation surveys
performed by CMS, or its agent(s).
III. Evaluation of the A2LA Request for Approval as an Accreditation
Organization Under CLIA
The following describes the process used to determine that the A2LA
accreditation program meets the necessary requirements to be approved
by CMS and that, as such, we may approve the A2LA as an accreditation
program with deeming authority under the CLIA program. The A2LA
formally applied to CMS for approval as an accreditation organization
under CLIA for all specialties and subspecialties.
In reviewing these materials, we reached the following
determinations for each applicable part of the CLIA regulations:
A. Subpart E--Accreditation by a Private, Nonprofit Accreditation
Organization or Exemption Under an Approved State Laboratory Program
The A2LA submitted its mechanism for monitoring compliance with all
requirements equivalent to condition-level requirements, a list of all
its current laboratories and the expiration date of their
accreditation, and a detailed comparison of the individual
accreditation requirements with the comparable condition-level
requirements. We have determined that the A2LA policies and procedures
for oversight of laboratories performing all laboratory testing covered
by CLIA are equivalent to those required by our CLIA regulations in the
matters of inspection, monitoring proficiency testing (PT) performance,
investigating complaints, and making PT information available. The A2LA
submitted documentation regarding its requirements for monitoring and
inspecting laboratories and describing its own standards regarding
accreditation organization data management, inspection processes,
procedures for removal or withdrawal of accreditation, notification
requirements, and accreditation organization resources. We have
determined that the requirements of the accreditation program submitted
for approval are equal to or more stringent than the requirements of
the CLIA regulations.
B. Subpart H--Participation in Proficiency Testing for Laboratories
Performing Nonwaived Testing
We have determined that the A2LA's requirements are equal to or
more stringent than the CLIA requirements at Sec. Sec. 493.801 through
493.865. Consistent with the CLIA requirements, all of the A2LA's
accredited laboratories are required to participate in an HHS-approved
PT program for tests listed in subpart I. The CLIA requirement at Sec.
493.801(b)(6) requires PT activities for the primary methods for
nonwaived testing, whereas the A2LA requires its accredited
laboratories to conduct PT activities for both primary and secondary
test systems for waived and non-waived testing.
C. Subpart J--Facility Administration for Nonwaived Testing
The A2LA's requirements are equal to or more stringent than the
CLIA requirements at Sec. Sec. 493.1100 through 493.1105.
D. Subpart K--Quality System for Nonwaived Testing
We have determined that the quality control requirements of the
A2LA are equal to or more stringent than the CLIA requirements at
Sec. Sec. 493.1200 through 493.1299.
E. Subpart M--Personnel for Nonwaived Testing
We have determined that the A2LA's requirements are equal to or
more stringent than the CLIA requirements at Sec. Sec. 493.1403
through 493.1495 for laboratories that perform moderate and high
complexity testing.
F. Subpart Q--Inspection
We have determined that the A2LA's inspection requirements are
equal to or more stringent than the CLIA requirements at Sec. Sec.
493.1771 through 493.1780. The A2LA will continue to conduct biennial
onsite inspections. The A2LA requires annual review of all accredited
laboratories. Laboratories are required to submit any updates on
information about its organization, facilities, key personnel, and
results of any proficiency testing. Laboratories may be required to
undergo an onsite surveillance visit if they do not submit their annual
review documentation to the A2LA by the established 30-day deadline, if
significant changes to the facility or organization have occurred, or
if proficiency testing results have been consistently poor. The CLIA
regulations do not have these requirements.
G. Subpart R--Enforcement Procedures
We have determined that A2LA meets the requirements of subpart R to
the extent that it applies to accreditation organizations. The A2LA
policy sets forth the actions the organization takes when laboratories
it accredits do not comply with its requirements and standards for
accreditation. When appropriate, the A2LA will deny, suspend, or revoke
accreditation in a laboratory accredited by A2LA and report that action
to us within 30 days. A2LA also provides an appeals process for
laboratories that have had accreditation denied, suspended, or revoked.
We have determined that the A2LA's laboratory enforcement and
appeal policies are equal to or more stringent than the requirements of
part 493, subpart R, as they apply to accreditation organizations.
IV. Federal Validation Inspections and Continuing Oversight
The Federal validation inspections of laboratories accredited by
the A2LA may be conducted on a representative sample basis or in
response to substantial allegations of noncompliance (that is,
complaint inspections). The outcome of those validation inspections,
performed by CMS or our agents, or the State survey agencies, will be
our principal means for verifying that the laboratories accredited by
the A2LA remain in compliance with CLIA requirements. This Federal
monitoring is an ongoing process.
V. Removal of Approval as an Accrediting Organization
Our regulations provide that we may rescind the approval of an
accreditation organization, such as that of the A2LA, for cause, before
the end of the effective date of approval. If we determine that the
A2LA has failed to adopt, maintain, and enforce requirements that are
equal to, or more stringent than, the CLIA requirements, or that
systemic problems exist in its monitoring, inspection or enforcement
processes, we may impose a probationary period, not to exceed 1 year,
in which the A2LA would be allowed to address any identified issues.
Should the A2LA be unable to address the identified issues within that
timeframe, we may, in accordance with the applicable regulations,
revoke the A2LA's deeming authority under CLIA.
Should circumstances result in our withdrawal of the A2LA's
approval, we will publish a notice in the Federal Register explaining
the basis for removing its approval.
VI. Collection of Information Requirements
This document does not impose information collection requirements,
that is, reporting record keeping or third party disclosure
requirements. Consequently, there is no need for review by the Office
of Management and Budget (OMB) under the authority of the
[[Page 16192]]
Paperwork Reduction Act of 1995 (44 U.S.C. 35). The requirements
associated with the accreditation process for clinical laboratories
under the CLIA program, and the implementing regulations in 42 CFR part
493, subpart E, are currently approved under OMB control number 0938-
0686.
VII. Executive Order 12866 Statement
In accordance with the provisions of Executive Order 12866, this
notice was not reviewed by the Office of Management and Budget.
The Administrator of the Centers for Medicare & Medicaid Services
(CMS), Chiquita Brooks-LaSure, having reviewed and approved this
document, authorizes Lynette Wilson, who is the Federal Register
Liaison, to electronically sign this document for purposes of
publication in the Federal Register.
Dated: March 17, 2022.
Lynette Wilson,
Federal Register Liaison, Centers for Medicare & Medicaid Services.
[FR Doc. 2022-06023 Filed 3-21-22; 8:45 am]
BILLING CODE 4120-01-P
</pre></body>
</html>Indexed from Federal Register on March 22, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.